{"schema":"sb.node.v1","id":"sb:e/5ad1cff5a387b4f823ac3920","kind":"entity","label":{"text":"novartis","locale":"en"},"identity":{"anchor":"label:en:novartis","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-09T23:33:39.923351+00:00","snapshot":"deploy 83f214d8604998c35ec5221eefec67f39f97c273"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":139,"separatePublishers":46,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim"},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-08-01","to":"2026-10-08","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.216: about 78% of mentions carry no typed assertion"]}},"dimensions":{"domains":["auto","biotech_pharma","fda_decisions"],"activeDays":33,"assertions":{"regulatory-approval":10,"funding-round":4,"launch-release":3,"military-action":2,"rate-decision":2,"acquisition":2}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":10,"byKind":{"observation":10},"withheld":{"state":"withheld","count":2,"reason":"2 receipts withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/c309c8d3a66fd06cbe2bb3ee","kind":"observation","label":"Endpoints News · 2026-10-07 · Novartis-partnered biotech nabs $150M Series B to move into the clinic","url":"https://endpoints.news/novartis-partnered-biotech-gets-150m-series-b-to-move-into-the-clinic/"},{"id":"sb:o/8ad7b012ef465d022d6c4a57","kind":"observation","label":"BioPharma Dive · 2026-10-05 · Novartis wagers almost $8B on a Chinese biotech’s RNA drugs","url":"https://www.biopharmadive.com/news/novartis-abogen-pipeline-collaboration-china/832008/"},{"id":"sb:o/ffe356a3f8154927f05349cf","kind":"observation","label":"Pulse 2.0 · 2026-10-03 · Novartis Signs Up To $7.8 Billion Licensing Deal With Abogen For mRNA-Encoded T-Cell Engager","url":"https://pulse2.com/novartis-signs-up-to-7-8-billion-licensing-deal-with-abogen-for-mrna-encoded-t-cell-engager/"},{"id":"sb:o/198bda01146c80e94d44196a","kind":"observation","label":"Fierce Pharma · 2026-10-02 · Proposed nuclear safety rules threaten to stall Novartis’ Pluvicto expansion","url":"https://www.fiercepharma.com/pharma/proposed-nuclear-safety-rules-threaten-stall-novartis-pluvicto-expansion"},{"id":"sb:o/59eb4badc08d9519fb2dd429","kind":"observation","label":"Endpoints News · 2026-10-02 · Novartis takes rights to Abogen's mRNA T cell engager for $575M upfront","url":"https://endpoints.news/novartis-takes-rights-to-abogens-mrna-t-cell-engager-for-575m-upfront/"},{"id":"sb:o/1074f399c9bde2a44504d657","kind":"observation","label":"AllSci News · 2026-10-02 · Novartis pays USD 575m upfront for Abogen’s mRNA-encoded in vivo autoimmune TCE","url":"https://allsci.com/news/licensing-and-partnerships/abogen-novartis-deal-secures-usd-575m-upfront/"},{"id":"sb:o/46fb01cd514002e99e14a40f","kind":"observation","label":"AllSci News · 2026-10-01 · Novartis and CAS build reaction-data backbone for AI drug discovery","url":"https://allsci.com/news/licensing-and-partnerships/ai-drug-discovery-platform-cas-and-novartis/"},{"id":"sb:o/ebc79fdb42aabdde6af8da0e","kind":"observation","label":"Clinical Trials Arena · 2026-09-25 · Roche targets Novartis on IgAN market after Phase III win","url":"https://www.clinicaltrialsarena.com/news/roche-targets-novartis-on-igan-market-after-phase-iii-win/"},{"id":"sb:o/74eafeef9e44faa6ab070a8d","kind":"observation","label":"Endpoints News · 2026-09-23 · Amgen's Phase 3 Sjögren's win; Novartis' $900M radioligand deal","url":"https://endpoints.news/amgens-phase-3-sjogrens-win-novartis-900m-radioligand-deal/"},{"id":"sb:o/35f6692d3408fdd67e8b276d","kind":"observation","label":"Fierce Pharma · 2026-09-17 · Legend Biotech names Novartis veteran Ingrid Zhang as new CEO","url":"https://www.fiercepharma.com/pharma/legend-biotech-names-novartis-veteran-ingrid-zhang-new-ceo"}],"cursor":null,"order":"newest first; we keep the 10 newest receipts for this entity. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with roche (43 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/ae48fccd869c932f045589d8"},{"kind":"relation","label":"co-mentioned with astrazeneca (42 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/e619c87e8d550acd872566af"},{"kind":"relation","label":"co-mentioned with fda (41 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/e2df7a99e49779dabf354d2c"},{"kind":"relation","label":"co-mentioned with eli lilly (39 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/d7d3f3adc4f766b96328dfc5"},{"kind":"relation","label":"co-mentioned with ai (33 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/68c1264dbadb509b349662e8"},{"kind":"relation","label":"co-mentioned with china (32 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/7054287a0cd7c2cf7eae9399"},{"kind":"relation","label":"co-mentioned with merck (31 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/400199caf0c61a6978b10108"},{"kind":"relation","label":"co-mentioned with clinical trials (31 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/04c96a3def4f09a7052b75d9"},{"kind":"relation","label":"co-mentioned with amgen (27 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/c93b03375e8b448be8f489cb"},{"kind":"relation","label":"co-mentioned with pfizer (25 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/985a76bc144b6b775ed3563e"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/5ad1cff5a387b4f823ac3920","mcp":"traverse {\"id\":\"sb:e/5ad1cff5a387b4f823ac3920\"}","page":"/entity/novartis/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/5ad1cff5a387b4f823ac3920\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/5ad1cff5a387b4f823ac3920\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/5ad1cff5a387b4f823ac3920\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/5ad1cff5a387b4f823ac3920\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}